Growth Hormone
CJC-1295
Long-acting GHRH analogue available with or without the DAC albumin-binding tail.
- Half-life
- No-DAC: ~30 min. DAC: ~6–8 days.
- Route
- Subcutaneous
Overview
CJC-1295 is a modified GHRH(1–29) analogue. The DAC (drug-affinity complex) version binds serum albumin and extends the half-life to roughly a week; the no-DAC version (often called Modified GRF 1–29) behaves like sermorelin with slightly better stability.
Mechanism of action
GHRH-receptor agonism at the pituitary. DAC variant produces a sustained GH/IGF-1 bleed; no-DAC preserves pulsatility.
Evidence base
Phase 1/2 studies of CJC-1295 DAC showed sustained IGF-1 elevation for up to 11 days after a single dose. Development was halted after a death in an unrelated trial arm.
Typical dosing
No-DAC: 100 mcg subcutaneously up to 3× daily, usually paired with ipamorelin. DAC: 1–2 mg weekly (higher IGF-1 sustain but flatter GH curve). Open the dose calculator →
Safety & contraindications
Injection-site reactions, transient flushing. The sustained GH elevation from DAC blunts natural pulsatility and raises theoretical concern for insulin resistance and edema at higher doses.
Common stacks
CJC-1295 (no-DAC) + ipamorelin is the archetypal GH-optimisation stack.
Related peptides
Educational reference only. Nothing on this page is medical advice, a prescription, or an offer to sell. Discuss any peptide therapy with a qualified clinician who can evaluate your history and monitoring needs.